Reunion Neuroscience Inc
Change company Symbol lookup
Select an option...
REUN Reunion Neuroscience Inc
HOV Hovnanian Enterprises Inc
SIRI Sirius XM Holdings Inc
NVEI Nuvei Corp
JNJ Johnson & Johnson
AVGO Broadcom Inc
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ABBV Abbvie Inc
CIEN Ciena Corp

Health Care : Health Care Providers & Services | Small Cap Growth
Based in Canada
Company profile

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Day's Change
-0.03 (-2.36%)
B/A Size
Day's High
Day's Low

Today's volume of 1,636 shares is on pace to be much lighter than REUN's 10-day average volume of 8,658 shares.




6 providers
December 06, 2022
November 18, 2022
November 14, 2022
November 07, 2022
October 31, 2022
October 24, 2022
October 12, 2022
October 07, 2022
October 03, 2022
September 29, 2022
September 28, 2022
September 19, 2022
Thinking about buying stock in Reunion Neuroscience, bluebird bio, Reviva Pharmaceuticals, Theravance Biopharma, or Broadwind?

InvestorsObserver issues critical PriceWatch Alerts for REUN, BLUE, RVPH, TBPH, and BWEN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.